|Bid||310.00 x N/A|
|Ask||333.00 x N/A|
|Day's range||318.00 - 329.50|
|52-week range||241.17 - 337.40|
|Beta (5Y monthly)||N/A|
|PE ratio (TTM)||N/A|
|Earnings date||06 Mar 2023|
|Forward dividend & yield||N/A (N/A)|
|1y target est||321.92|
(Bloomberg) -- Haleon Plc, the consumer health business spun out from British pharmaceutical producer GSK Plc, is in the early stages of studying large potential deals to bulk up its brand portfolio, people with knowledge of the matter said. Most Read from BloombergSony Slashes PlayStation VR2 Headset Output After Pre-Orders DisappointPutin’s War in Ukraine Pushes Ex-Soviet States Toward New AlliesBrexit Is Costing the UK £100 Billion a Year in Lost OutputTrump Sues Journalist Bob Woodward for R
Dr James Fox explains why he's bought two cheap shares with the aim of holding them for three decades. But what are they? The post 2 dirt-cheap shares I’ve bought to hold for 30 years! appeared first on The Motley Fool UK.
GSK's specialty products like Dovato, Nucala, Trelegy Ellipta and Shingrix are likely to drive sales, making up for the lower sales of established drugs due to generic erosion.